| Dr Holly L Hanson, MD, PHD | |
|
1951 Clairmont Rd, Decatur, GA 30033-3415 | |
| (404) 508-0566 | |
| (404) 508-0567 |
| Full Name | Dr Holly L Hanson |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 20 Years |
| Location | 1951 Clairmont Rd, Decatur, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174709711 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 000810 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Associates Of Georgia, Llc | 3678547569 | 13 |
News Archive
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Hospital for Special Surgery, the nation's top hospital for orthopedics, will host Current Concepts in Sports Medicine, an educational symposium to discuss how to identify, prevent and treat articular cartilage and hip/pelvis injuries, as well as injuries common to the throwing and multisport athlete.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.
The lack of a single protein usually thought of as a run-of-the-mill enzyme that helps to recycle molecules in cells causes an incurable and often fatal disease of children, according to St. Jude Children's Research Hospital investigators.
› Verified 1 days ago
| Entity Name | Dermatology Associates Of Georgia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063560803 PECOS PAC ID: 3678547569 Enrollment ID: O20040825001091 |
News Archive
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Hospital for Special Surgery, the nation's top hospital for orthopedics, will host Current Concepts in Sports Medicine, an educational symposium to discuss how to identify, prevent and treat articular cartilage and hip/pelvis injuries, as well as injuries common to the throwing and multisport athlete.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.
The lack of a single protein usually thought of as a run-of-the-mill enzyme that helps to recycle molecules in cells causes an incurable and often fatal disease of children, according to St. Jude Children's Research Hospital investigators.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Holly L Hanson, MD, PHD 2665 N Decatur Rd, Suite 650, Decatur, GA 30033-6149 Ph: (404) 508-0566 | Dr Holly L Hanson, MD, PHD 1951 Clairmont Rd, Decatur, GA 30033-3415 Ph: (404) 508-0566 |
News Archive
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Hospital for Special Surgery, the nation's top hospital for orthopedics, will host Current Concepts in Sports Medicine, an educational symposium to discuss how to identify, prevent and treat articular cartilage and hip/pelvis injuries, as well as injuries common to the throwing and multisport athlete.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.
The lack of a single protein usually thought of as a run-of-the-mill enzyme that helps to recycle molecules in cells causes an incurable and often fatal disease of children, according to St. Jude Children's Research Hospital investigators.
› Verified 1 days ago
Dr. Carl V Washington, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1951 Clairmont Rd, Decatur, GA 30033 Phone: 404-321-4600 Fax: 404-320-0987 | |
Dr. Kathleen Jeanne Smith, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1670 Scott Blvd Ste 202, Decatur, GA 30033 Phone: 678-904-4932 Fax: 470-428-2869 | |
Dr. Jordan Sern Yuang Lim, MD Dermatology Medicare: Medicare Enrolled Practice Location: 250 N Arcadia Ave, Decatur, GA 30030 Phone: 404-329-2222 | |
Damon Van Mauldin, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1951 Clairmont Rd, Decatur, GA 30033 Phone: 404-321-4600 Fax: 404-320-0987 | |
Lakenya Odom, Dermatology Medicare: Not Enrolled in Medicare Practice Location: 18004 Anwar Trl, Decatur, GA 30032 Phone: 678-668-4183 | |
Marcus R Stonecipher, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1951 Clairmont Rd, Decatur, GA 30033 Phone: 404-321-4600 Fax: 404-320-0987 |